NOVELTY at ERS 2023
Ten NOVELTY abstracts have been presented at ERS 2023.Read More
If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.
The NOVEL observational longiTudinal studY (NOVELTY) is a global, prospective, 3-year observational study of patients with a diagnosis or suspected diagnosis of asthma and/or COPD, with an additional 2-year extension study at participating sites. NOVELTY aims to describe patient characteristics, treatment patterns and disease burden over time across the spectrum of obstructive lung disease, providing real-world evidence to advance the development of precision medicine to deliver the right treatment to the right patient at the right time. The NOVELTY study is sponsored by AstraZeneca.
Now published in Respiratory Research: Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD.Read More
Now published in ERJ Open Research: Functional imaging in asthma and COPD: design of the NOVELTY ADPro substudy.Read More
Read summaries of publications and presentations relating to the NOVELTY study and access useful NOVELTY resources.Read More
Access news updates, research requests, resources and frequently asked questions relating to the NOVELTY study.Read More